ECSP11010807A - Sales de los compuestos del inhibidor de vih - Google Patents

Sales de los compuestos del inhibidor de vih

Info

Publication number
ECSP11010807A
ECSP11010807A EC2011010807A ECSP11010807A ECSP11010807A EC SP11010807 A ECSP11010807 A EC SP11010807A EC 2011010807 A EC2011010807 A EC 2011010807A EC SP11010807 A ECSP11010807 A EC SP11010807A EC SP11010807 A ECSP11010807 A EC SP11010807A
Authority
EC
Ecuador
Prior art keywords
salts
inhibitor compounds
hiv inhibitor
hiv
administration
Prior art date
Application number
EC2011010807A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Graetz
Richard Polniaszek
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ECSP11010807A publication Critical patent/ECSP11010807A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EC2011010807A 2008-07-08 2011-02-03 Sales de los compuestos del inhibidor de vih ECSP11010807A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7898908P 2008-07-08 2008-07-08

Publications (1)

Publication Number Publication Date
ECSP11010807A true ECSP11010807A (es) 2011-09-30

Family

ID=41055429

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010807A ECSP11010807A (es) 2008-07-08 2011-02-03 Sales de los compuestos del inhibidor de vih

Country Status (26)

Country Link
US (6) US8658617B2 (enExample)
EP (1) EP2307435B1 (enExample)
JP (2) JP5620376B2 (enExample)
KR (1) KR101642527B1 (enExample)
CN (1) CN102089318B (enExample)
AP (1) AP3347A (enExample)
AU (1) AU2009268681B2 (enExample)
BR (1) BRPI0915878A2 (enExample)
CA (1) CA2729769C (enExample)
CL (1) CL2011000014A1 (enExample)
CO (1) CO6321288A2 (enExample)
CY (1) CY1113240T1 (enExample)
DK (1) DK2307435T3 (enExample)
EA (1) EA018308B1 (enExample)
EC (1) ECSP11010807A (enExample)
ES (1) ES2393962T3 (enExample)
HR (1) HRP20120700T1 (enExample)
IL (1) IL210006A (enExample)
MX (1) MX2011000306A (enExample)
NZ (1) NZ590075A (enExample)
PE (1) PE20110219A1 (enExample)
PL (1) PL2307435T3 (enExample)
PT (1) PT2307435E (enExample)
UA (1) UA103329C2 (enExample)
WO (1) WO2010005986A1 (enExample)
ZA (1) ZA201100694B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2006110157A2 (en) * 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
HRP20120700T1 (hr) * 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
WO2012138907A2 (en) * 2011-04-05 2012-10-11 Translational Genomics Research Institute Solid forms of curcumin
EP3450438A1 (en) * 2011-05-19 2019-03-06 Gilead Sciences, Inc. Processes and intermediates for preparing anti-hiv agents
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
US20180085387A1 (en) * 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Family Cites Families (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4649041A (en) 1983-07-20 1987-03-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antinauseants
DK159431C (da) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5455339A (en) 1986-05-01 1995-10-03 University Of Georgia Research Foundation, Inc. Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
FR2611203B1 (fr) 1987-02-20 1989-06-09 Sturtz Georges Analogues gem-diphosphoniques d'amethopterine (methotrexate) et de derives deaza-n-10 amethopterine. leur preparation et les compositions pharmaceutiques qui les contiennent
JP2737191B2 (ja) * 1987-12-28 1998-04-08 東ソー株式会社 均質な石英ガラス塊の製造方法
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5466793A (en) 1988-03-01 1995-11-14 Ajinomoto Co., Inc. Process for preparing 2', 3'- dideoxyinosine
ZA894534B (en) 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
JP2722673B2 (ja) 1989-05-31 1998-03-04 住友化学工業株式会社 光学活性なアシルビフェニル誘導体の製造法
DE4003574A1 (de) 1990-02-07 1991-08-08 Bayer Ag Neue dipeptide, verfahren zu ihrer herstellung und ihre verwendung als renininhibitoren in arzneimitteln
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
DK0465297T3 (da) 1990-07-04 1996-02-19 Merrell Pharma Inc 9-Purinylphosphonsyre-derivater
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
EP0468119A1 (en) 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
ES2118069T3 (es) 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
DE4111730A1 (de) 1991-04-10 1992-10-15 Knoll Ag Neue cytarabin-derivate, ihre herstellung und verwendung
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0531597A1 (en) 1991-09-12 1993-03-17 Merrell Dow Pharmaceuticals Inc. Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine
US5610294A (en) 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
DE4138584A1 (de) 1991-11-23 1993-05-27 Hoechst Ag Carbocyclische phosphonat-nucleotidanaloge, deren herstellung und verwendung
GB9126144D0 (en) 1991-12-10 1992-02-12 British Bio Technology Compounds
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
AU7491694A (en) 1993-07-14 1995-02-13 Ciba-Geigy Ag Cyclic hydrazine compounds
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5493030A (en) 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5854227A (en) 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
FI971234A7 (fi) 1994-09-26 1997-05-23 Shionogi & Co Imidatsolijohdannainen
WO1996014314A2 (en) 1994-11-04 1996-05-17 Gilead Sciences, Inc. Thiepane compounds inhibiting and detecting hiv protease
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
ES2097703B1 (es) 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6299496A (en) 1995-06-29 1997-01-30 Novo Nordisk A/S Novel substituted azabicyclic compounds
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
EP0852233A4 (en) 1995-09-21 1999-09-15 Nippon Shinyaku Co Ltd CYCLOSPORIN PHOSPHATE DERIVATIVES AND MEDICINAL COMPOSITION
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
RU2106353C1 (ru) 1996-03-19 1998-03-10 Корпорация "С энд Ти Сайенс энд Текнолоджи Инк." Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2
US5656746A (en) * 1996-03-28 1997-08-12 The Proctor & Gamble Company Temporary wet strength polymers from oxidized reaction product of polyhydroxy polymer and 1,2-disubstituted carboxylic alkene
US5874577A (en) 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
JP4033494B2 (ja) 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
KR20000029952A (ko) 1996-08-13 2000-05-25 미우라 아끼라 포스포네이트뉴클레오티드화합물
CA2266404A1 (en) 1996-09-17 1998-03-26 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
PT934325E (pt) 1996-10-09 2004-10-29 Pharmasset Ltd Trisanidridos biciclicos de tetrafosfonato
JP3378016B2 (ja) 1996-12-26 2003-02-17 塩野義製薬株式会社 カルバモイル基を有するイミダゾール誘導体の製造法
WO1999029702A2 (en) 1997-12-10 1999-06-17 The Government Of The United States Of America Reppresented By The Secretary, Department Of Health And Human Services METHOD FOR SYNTHESIZING 9-(2,3-DIDEOXY-2-FLUORO-β-D-THREO-PENTOFURANOSYL)ADENINE (β-FddA)
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
WO1999062921A1 (en) 1998-06-01 1999-12-09 S & T Science And Technology Inc. Antiviral phosphorus derivatives of 4'-thio-5-ethyl-2'-deoxyuridine
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP5063837B2 (ja) 1999-03-05 2012-10-31 リガンド・ファーマシューティカルズ・インコーポレイテッド 新規リン含有プロドラッグ
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
US6258831B1 (en) 1999-03-31 2001-07-10 The Procter & Gamble Company Viral treatment
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19927689A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
CA2377278C (en) 1999-06-25 2010-03-23 Vertex Pharmaceuticals Incorporated Prodrugs of carbamate inhibitors of impdh
US6581606B2 (en) 1999-07-06 2003-06-24 The Rx Files Corporation Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
GB9920872D0 (en) 1999-09-04 1999-11-10 Glaxo Group Ltd Benzophenones as inhibitors of reverse transcriptase
IL131887A0 (en) 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
BR0016058A (pt) 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
JP2003518128A (ja) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなる芳香族ホスホネート
CN1426418A (zh) 2000-02-29 2003-06-25 三菱制药株式会社 膦酸酯核苷酸化合物
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153363A0 (en) 2000-06-13 2003-07-06 Shionogi & Co Pharmaceutical compositions containing propenone derivatives
FR2810322B1 (fr) 2000-06-14 2006-11-10 Pasteur Institut PRODUCTION COMBINATOIRE D'ANALOGUES DE NUCLEOTIDES ET NUCLEOTIDES (XiTP)
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6617310B2 (en) 2000-07-19 2003-09-09 Bristol-Myers Squibb Pharma Company Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines
DK1301519T4 (da) 2000-07-21 2021-12-20 Gilead Sciences Inc Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
US6420586B1 (en) 2000-08-15 2002-07-16 University Of Kansas Amino acid-derived cyclic phosphonamides and methods of synthesizing the same
DE60124117T8 (de) 2000-09-08 2007-05-31 Zeria Pharmaceutical Co., Ltd. Aminothiazol-derivate enthaltende pharmazeutische zusammensetzungen zur behandlung von motorischen störungen des kolons
RU2188203C2 (ru) 2000-10-05 2002-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" 2',3'-дидегидро-2',3'-дидезокситимидин-5'[(этоксикарбонил)(этил)фосфонат]- ингибитор репродукции вируса иммунодефицита человека
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
BR0116221A (pt) 2000-12-15 2005-09-13 Pharmasset Ltd Agentes antivirais para tratamento de infecções por flaviviridae
JP4035052B2 (ja) * 2000-12-28 2008-01-16 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
CA2433364A1 (en) 2001-01-31 2002-08-08 James Edward Ellis Method for carbamoylating alcohols
JP4220243B2 (ja) 2001-02-12 2009-02-04 ワイス Ｏ−デスメチル−ベンラファキシンの新規コハク酸塩
EP1262458B1 (en) 2001-05-31 2008-03-05 Sumitomo Chemical Company, Limited Method for producing an activated alumina formed body
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
KR20020097384A (ko) 2001-06-20 2002-12-31 미쯔비시 도꾜 세이야꾸 가부시끼가이샤 기존의 약제에 내성변이를 가지는 바이러스에 유효한 약제
WO2002103008A2 (en) 2001-06-20 2002-12-27 Nuevolution A/S Templated molecules and methods for using such molecules
WO2003009855A2 (de) 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ES2330089T3 (es) 2001-08-17 2009-12-04 Mitsui Chemicals Agro, Inc. Derivado de 3-fenoxi-4-piridazinol y composicion herbicida que lo contiene.
WO2003028737A1 (en) 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
ES2258652T3 (es) * 2001-11-29 2006-09-01 Pfizer Products Inc. Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos.
AU2002343556A1 (en) 2001-12-07 2003-06-23 Eli Lilly And Company Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
EP1456199A1 (en) 2001-12-12 2004-09-15 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
KR20100101011A (ko) 2001-12-21 2010-09-15 에이자이 아이엔씨. 알콜 및 페놀의 수용성 포스포노옥시메틸 유도체를 제조하는 방법
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
CA2474508A1 (en) 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003216523A1 (en) 2002-03-18 2003-10-08 Mitsubishi Pharma Corporation Treatment of pre-core hepatitis b virus mutant infections
EP1495017A2 (en) 2002-04-10 2005-01-12 Ortho-McNeil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US6872827B2 (en) 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
JP4942915B2 (ja) 2002-04-26 2012-05-30 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積
US6808572B2 (en) * 2002-05-15 2004-10-26 Aerojet-General Corporation Solid propellant formulations and methods and devices employing the same for the destruction of airborne biological and/or chemical agents
US7964734B2 (en) 2002-09-30 2011-06-21 A/S Gea Farmaceutisk Fabrik Raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
AU2003290816A1 (en) 2002-11-12 2004-06-03 Pharmasset, Inc. Modified nucleosides as antiviral agents
AU2004260630B2 (en) 2003-02-19 2009-12-10 Masanori Baba Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
WO2004100960A2 (en) 2003-04-25 2004-11-25 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
WO2004096237A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004096233A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Nucleoside phosphonate conjugates
WO2004096236A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Immunomodulator phosphonate conjugates
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
KR20060061930A (ko) 2003-04-25 2006-06-08 길리애드 사이언시즈, 인코포레이티드 항암성 포스포네이트 유사체
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005000786A1 (en) 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
CA2727748A1 (en) 2003-06-16 2004-12-23 Ajinomoto Co., Inc. Inosine derivatives and production methods therefor
AU2004260789B2 (en) 2003-07-30 2011-06-30 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
EP1658276B1 (en) 2003-08-18 2012-10-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
EP1678321A1 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2548951A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
EP1550665A1 (en) 2003-12-26 2005-07-06 Ajinomoto Co., Inc. A process for the production of purine nucleoside compounds
US7404949B2 (en) 2004-03-15 2008-07-29 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Methods and compositions useful to prevent in-grown hair arising from shaving
CA2570389A1 (en) 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
WO2006110157A2 (en) * 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
WO2006015262A2 (en) 2004-07-29 2006-02-09 Coherix, Inc. Method for processing multiwavelength interferometric imaging data
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7154505B2 (en) 2004-11-11 2006-12-26 Stonecube Limited Method of and apparatus for generating a representation of an object
KR20060080817A (ko) 2005-01-06 2006-07-11 씨제이 주식회사 시부트라민의 디카복실산염
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US20080279932A1 (en) 2005-08-04 2008-11-13 Jean-Louis Reber Compounds
DE102005041860A1 (de) 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US20070149552A1 (en) * 2005-12-16 2007-06-28 Wyeth Lyophilized compositions of a triazolopyrimidine compound
US20060223820A1 (en) 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
CN101495294B (zh) * 2006-05-26 2013-03-13 3D系统公司 用于处理三维打印机中材料的装置和方法
LT2487163T (lt) 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
US20090163449A1 (en) 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
HRP20120700T1 (hr) * 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
JP4330086B1 (ja) 2009-02-09 2009-09-09 株式会社テクネス 非酸化物セラミックス製品の製造方法
EP2305680A3 (en) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
US20140094609A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor

Also Published As

Publication number Publication date
EP2307435B1 (en) 2012-06-13
US20110144050A1 (en) 2011-06-16
US20160355543A1 (en) 2016-12-08
DK2307435T3 (da) 2012-09-10
ES2393962T3 (es) 2013-01-03
US20100093667A1 (en) 2010-04-15
US20140227224A1 (en) 2014-08-14
UA103329C2 (ru) 2013-10-10
WO2010005986A1 (en) 2010-01-14
HK1156633A1 (en) 2012-06-15
CL2011000014A1 (es) 2011-05-13
EA201071367A1 (ru) 2011-08-30
EA018308B1 (ru) 2013-07-30
US20150182547A1 (en) 2015-07-02
US20180079772A1 (en) 2018-03-22
EP2307435A1 (en) 2011-04-13
US9783568B2 (en) 2017-10-10
JP2011527687A (ja) 2011-11-04
MX2011000306A (es) 2011-03-15
ZA201100694B (en) 2013-04-24
KR20110029165A (ko) 2011-03-22
AP2010005509A0 (en) 2010-12-31
CY1113240T1 (el) 2016-04-13
AP3347A (en) 2015-07-31
AU2009268681B2 (en) 2014-10-02
CN102089318A (zh) 2011-06-08
CO6321288A2 (es) 2011-09-20
PE20110219A1 (es) 2011-03-31
US8951986B2 (en) 2015-02-10
BRPI0915878A2 (pt) 2015-11-03
KR101642527B1 (ko) 2016-07-25
AU2009268681A1 (en) 2010-01-14
NZ590075A (en) 2012-12-21
CA2729769C (en) 2017-09-05
US8658617B2 (en) 2014-02-25
JP5620376B2 (ja) 2014-11-05
PL2307435T3 (pl) 2012-11-30
JP2014122235A (ja) 2014-07-03
IL210006A0 (en) 2011-02-28
CA2729769A1 (en) 2010-01-14
IL210006A (en) 2016-02-29
CN102089318B (zh) 2014-05-21
US9381206B2 (en) 2016-07-05
HRP20120700T1 (hr) 2012-09-30
PT2307435E (pt) 2012-09-19

Similar Documents

Publication Publication Date Title
ECSP11011517A (es) Compuestos antivirales
CO2018002063A2 (es) Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih
UY33735A (es) Compuestos antivirales
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
ECSP109904A (es) Compuestos antivirales
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
CO7400867A2 (es) Modificador del sabor dulce
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
CR20140554A (es) Compuestos de acido dimetil-benzoico